First Patient Dosed in Ph 2 Study of Givastomig-Nivolumab combo in Patients with 1L Metastatic HER2-neg Gastric Cancer February 25, 2026
Planned Milestones in Ongoing Ph 2 DURIPANC Trial of Ampligen and Durvalumab in the Treatment of Metastatic Pancreatic Cancer Announced February 25, 2026
Tempest plans to prioritize development of clinical-stage dual-targeting CD19/BCMA CAR-T program, TPST-2003 February 17, 2026
US FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer February 17, 2026
Zenocutuzumab‑zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma February 9, 2026
FDA Accepted NDA for Zanzalintinib – Tecentriq Combo in Patients with Metastatic CRC February 9, 2026
Positive Year-End Interim Clinical Progress from Ph 2 Study of Ampligen – Imfinzi Combo in Pancreatic Cancer Reported February 9, 2026
First Patient Dosed in Ph 1a/2a Trial of DPTX3186 in Advanced Solid Tumors, Focused on Gastric Cancer February 9, 2026
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic CRPC February 9, 2026
Results announced from Ph 3 study of Anbenitamab (KN026) in HER2+ve gastric or gastroesophageal junction cancer (GC/GEJ) February 1, 2026
Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for GIST Patients February 1, 2026
First Patient Dosed in Ph 1 Trial of RMC-5127 in patients with RAS G12V–mutated solid tumors February 1, 2026
Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers February 1, 2026
